Does Empagliflozin Cause Hyperkalemia?
No, empagliflozin does not cause hyperkalemia—in fact, it reduces the risk of hyperkalemia, particularly in patients with chronic kidney disease or those taking renin-angiotensin-aldosterone system (RAAS) inhibitors.
Evidence from FDA Drug Label
The FDA prescribing information for empagliflozin (JARDIANCE) does not list hyperkalemia as a warning, precaution, or adverse reaction 111. The label focuses on other safety concerns including hypotension, ketoacidosis, urinary tract infections, and genital mycotic infections—but hyperkalemia is notably absent from the safety profile.
Clinical Trial Evidence: Empagliflozin Actually Reduces Hyperkalemia Risk
EMPEROR-Pooled Analysis (Most Definitive Evidence)
Empagliflozin significantly reduced hyperkalemia across multiple definitions 2:
- Composite outcome (investigator-reported hyperkalemia or potassium binder initiation): 6.5% vs 7.7% with placebo (HR 0.82,95% CI 0.71-0.95, P=0.01)
- Serum potassium >5.5 mmol/L: 8.6% vs 9.9% with placebo (HR 0.85, P=0.017)
- Serum potassium >6.0 mmol/L: 1.9% vs 2.9% with placebo (HR 0.62,95% CI 0.48-0.81, P<0.001)
- Importantly, empagliflozin did not increase hypokalaemia risk
Advanced CKD Population (Highest Risk Group)
In patients with type 2 diabetes and moderate to severe CKD (categories G3-4), empagliflozin demonstrated a protective effect against hyperkalemia 3:
- Significantly lower hyperkalemia risk in both G3B/G4 combined (HR 0.59,95% CI 0.37-0.96, P=0.0323) and G3A groups (HR 0.48,95% CI 0.26-0.91, P=0.0243)
- This is particularly important since CKD patients are at highest baseline risk for hyperkalemia
EMPEROR-Reduced: Interaction with Mineralocorticoid Receptor Antagonists
Empagliflozin's protective effect persisted even in patients taking MRAs (which themselves increase hyperkalemia risk) 4:
- Severe hyperkalemia was less common in the empagliflozin group
- Patients on empagliflozin were 22% less likely to discontinue MRAs (HR 0.78,95% CI 0.64-0.96)
- This suggests empagliflozin may enable continuation of guideline-directed medical therapy that would otherwise be limited by hyperkalemia
Guideline Recognition
The 2022 Canadian Cardiovascular Society guideline acknowledges this protective effect, noting that specialist referral for CKD should be considered for "inability to continue kidney-protective therapies because of adverse effects, such as hyperkalemia" after starting SGLT2i, ACEi, or ARB 5. The implication is that SGLT2 inhibitors like empagliflozin may actually help manage hyperkalemia rather than cause it.
Mechanism: Why Empagliflozin Protects Against Hyperkalemia
The physiologic explanation involves multiple offsetting effects 6:
- SGLT2 inhibition increases distal sodium delivery, which enhances potassium secretion
- Mild volume contraction may reduce aldosterone suppression
- These effects counterbalance any theoretical hyperkalemia risk
- Net result: neutral to protective effect on potassium homeostasis
Clinical Implications
When initiating empagliflozin:
- Do not withhold or discontinue RAAS inhibitors due to hyperkalemia concerns
- Empagliflozin may actually facilitate optimal dosing of ACEi/ARB/MRA therapy
- Monitor potassium as you would with any CKD patient, but empagliflozin itself is not a hyperkalemia risk factor
- Consider empagliflozin as part of the strategy to manage patients with recurrent hyperkalemia on RAAS inhibitors
Common pitfall to avoid: Do not confuse empagliflozin's safety profile with that of potassium-sparing diuretics or RAAS inhibitors. While these latter agents increase hyperkalemia risk, empagliflozin does the opposite.
The most recent high-quality evidence from the CONFIDENCE trial 7 showed that when empagliflozin was combined with finerenone (a nonsteroidal MRA), hyperkalemia occurred in 9.7% with empagliflozin alone versus 18.8% with finerenone alone—further confirming empagliflozin's protective effect.